EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2

These guidelines summarize the current views of the European Association of Nuclear Medicine Neuroimaging Committee (ENC). The aim of the guidelines is to assist nuclear medicine practitioners when making recommendations, performing, interpreting, and reporting the results of clinical dopamine transporter (DAT) single photon emission computed tomography (SPECT) studies using 123I-labelled radiopharmaceuticals. The aim is to achieve a high-quality standard of DAT SPECT imaging, which will increase the diagnostic impact of this technique in neurological practice. The present document is an update of the 2002 guidelines [1] and has been guided by the views of various national societies: the Task Group Neuro-Nuclear-Medicine of the German Society of Nuclear Medicine [2], a consensus statement of the imaging centres included in the “Kompetenznetz-Parkinson” sponsored by the German Federal Ministry of Education, and the Task Group of Neuro-Nuclear-Medicine of the French Society of Nuclear Medicine [3]. The guidelines reflect the individual experience of experts in European countries. The guidelines are intended to present information specifically adapted to European practice. The information provided should be taken in the context of local conditions and regulations.

[1]  P B Hoffer,et al.  [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. , 1996, Neurology.

[2]  J. Seibyl,et al.  [123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression , 2001, Neurology.

[3]  Jan Booij,et al.  Dopamine transporter imaging with [123I]FP-CIT SPECT: potential effects of drugs , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  C. Weiller,et al.  Clinical applications of single photon emission tomography in neuromedicine , 2000, Nuklearmedizin.

[5]  Michael G. Stabin,et al.  Human biodistribution and dosimetry of [123I]FP-CIT: a potent radioligand for imaging of dopamine transporters , 1997, European Journal of Nuclear Medicine.

[6]  E. Länsimies,et al.  The dosimetry of iodine-123 labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane. , 1994, European journal of nuclear medicine.

[7]  J. Seibyl,et al.  Whole-body biodistribution, radiation absorbed dose and brain SPECT imaging with iodine-123-beta-CIT in healthy human subjects. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  P Slomka,et al.  Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  G. Bernardi,et al.  The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  Elena Salvatore,et al.  Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  J D Speelman,et al.  [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[12]  Po See Chen,et al.  Decreased dopamine transporter availability in male smokers — A dual isotope SPECT study , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[13]  A Pupi,et al.  European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands. , 2002, European journal of nuclear medicine and molecular imaging.

[14]  J D Speelman,et al.  One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  Irène Buvat,et al.  Quantitative accuracy of dopaminergic neurotransmission imaging with (123)I SPECT. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  Perry E Radau,et al.  Is iterative reconstruction an alternative to filtered backprojection in routine processing of dopamine transporter SPECT studies? , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  Perry E Radau,et al.  Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  A. Kessels,et al.  Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes , 2007, BMC neurology.

[19]  Catafau Am,et al.  Brain SPECT of dopaminergic neurotransmission: a new tool with proved clinical impact. , 2001 .

[20]  E. Länsimies,et al.  The dosimetry of iodine-123 labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane , 2004, European Journal of Nuclear Medicine.

[21]  D J Wyper,et al.  Correlation of Parkinson's disease severity and duration with 123I‐FP‐CIT SPECT striatal uptake , 2000, Movement disorders : official journal of the Movement Disorder Society.

[22]  J. Seibyl,et al.  [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. , 2001, Neurology.

[23]  Yann Cointepas,et al.  Validation of a Standardized Normalization Template for Statistical Parametric Mapping Analysis of 123I-FP-CIT Images , 2007, Journal of Nuclear Medicine.

[24]  Dag Aarsland,et al.  Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. , 2004, Archives of neurology.

[25]  Piero Calvini,et al.  The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  C. Halldin,et al.  Brain radioligands--state of the art and new trends. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[27]  C. Tanner,et al.  Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.

[28]  I. McKeith,et al.  Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[29]  W. Weber,et al.  Role of DAT‐SPECT in diagnostic work‐up of Parkinsonism , 2008, Movement disorders : official journal of the Movement Disorder Society.

[30]  Philippe R. Franken,et al.  Influence of high-energy photons on the spectrum of iodine-123 with low- and medium-energy collimators: consequences for imaging with 123I-labelled compounds in clinical practice , 1999, European Journal of Nuclear Medicine.

[31]  I. McKeith,et al.  Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study , 2007, The Lancet Neurology.

[32]  K. Tatsch,et al.  Imaging of the dopaminergic system in parkinsonism with SPET , 2001, Nuclear medicine communications.

[33]  J. P. Seibyl,et al.  [sup 123 I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease , 1996, Neurology.